Johnson & Johnson Aktie News

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury today delivered a $40 million verdict against Johnson & Johnson. The trial featured two California women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory ...

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa. , Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA...

A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds.

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.

For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.

The US Equity Income Fund underperformed its benchmark, the Russell 1000 Value Index, net of fees during the third quarter. Enterprise software company, Oracle Corporation, was a top contributor to relative returns during the quarter. Our position in consumer healthcare company, Kenvue Inc., was a top detractor from relative performance during the month.

With the Federal Reserve set to announce its final policy decision of 2025 on Wednesday, investors are rotating into defensive positions. More than the rate-cut possibility (which is around 90% as per recent estimates), the traders are worried about whether the central bank will signal more easing ahead or take a harder stance.